| Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability PCT Md. Shafikur Rahman, Shikha Kumari, Shiva Hadi Esfahani, Saeideh ... Journal of Medicinal Chemistry, 2021 | 13 | 2021 |
| In-Vivo and Ex-Vivo Brain Uptake Studies of Peptidomimetic Neurolysin Activators in Healthy and Stroke Animals S Nozohouri, SH Esfahani, B Noorani, D Patel, H Villalba, Y Ghanwatkar, ... Pharmaceutical research 39 (7), 1587-1598, 2022 | 10 | 2022 |
| Identification and characterization of two structurally related dipeptides that enhance catalytic efficiency of neurolysin S Jayaraman, J Kocot, SH Esfahani, NJ Wangler, A Uyar, Y Mechref, ... Journal of Pharmacology and Experimental Therapeutics 379 (2), 191-202, 2021 | 9 | 2021 |
| Small molecule neurolysin activators, potential multi-mechanism agents for ischemic stroke therapy SH Esfahani, TJ Abbruscato, PC Trippier, VT Karamyan Expert Opinion on Therapeutic Targets 26 (5), 401-404, 2022 | 5 | 2022 |
| Structure-activity relationship studies of functionalized aromatic peptidomimetics as neurolysin activators MS Rahman, SH Esfahani, S Nozohouri, S Kumari, J Kocot, Y Zhang, ... Bioorganic & medicinal chemistry letters 64, 128669, 2022 | 4 | 2022 |
| Discovery of the Next Generation of Non-peptidomimetic Neurolysin Activators with High Blood-Brain Barrier Permeability: A Pharmacokinetics Study in Healthy and Stroke Animals Y Zhang, S Sharma, S Jonnalagadda, S Kumari, A Queen, SH Esfahani, ... Pharmaceutical Research 40 (11), 2747-2758, 2023 | 3 | 2023 |
| Imidazole Bioisostere Activators of Endopeptidase Neurolysin with Enhanced Potency and Metabolic Stability MS Rahman, S Hadi Esfahani, Y Zhang, A Queen, M Aljarrah, H Kandil, ... ACS Medicinal Chemistry Letters 15 (4), 510-517, 2024 | 1 | 2024 |
| Is diminazene an angiotensin-converting enzyme 2 (ACE2) activator? Experimental evidence and implications SH Esfahani, S Jayaraman, VT Karamyan Journal of Pharmacology and Experimental Therapeutics 383 (2), 149-156, 2022 | 1 | 2022 |
| Structural basis of divergent substrate recognition and inhibition of human neurolysin K Shi, S Bagchi, J Bickel, SH Esfahani, L Yin, T Cheng, VT Karamyan, ... Scientific reports 14 (1), 18420, 2024 | | 2024 |
| High brain-blood barrier permeability highlights a new class of neurolysin activators as promising candidates for stroke treatment: a pilot pharmacokinetic study in mice Y Zhang, S Sharma, SH Esfahani, S Jonnalagadda, A Queen, ... Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| Challenges with the proposed ACE2 activation mechanism of diminazene aceturate. SH Esfahani, VT Karamyan Clinical and Experimental Pharmacology & Physiology 49 (5), 608-610, 2022 | | 2022 |
| Evaluation of therapeutic goal achievements with once daily usual and high dosing of amikacin in elderly critically ill patients S Hadi Esfahani Tabriz University of Medical Sciences, Faculty of Pharmacy, 2016 | | 2016 |
| And Experimental Therapeutics F Mazzo, I Butnaru, O Grubisha, E Ficulle, H Sanger, G Fitzgerald, F Pan, ... | | |
